Microcap Ledger Cardio Diagnostics Holdings, Inc. $CDIO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- Chicago, IL
- Fiscal year end
- December 31
- Shares outstanding
- 2,959,469 [10-Q 2026-08-07]
What the company doesAI summary of filing
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical blood tests for cardiovascular disease using its proprietary AI-driven Multi-Omics Engine. The company's two main products are Epi+Gen CHD™, a three-year coronary heart disease event risk assessment test launched in 2021, and PrecisionCHD™, a coronary heart disease detection test launched in 2023. Both tests have received CPT codes and CMS gapfill reimbursement rates of $854 per test as of 2025. The company is pre-revenue to early-stage revenue-generating, selling tests through various channels including health systems, providers, employers, and payors, while pursuing broader payor coverage and considering an FDA regulatory pathway for wider laboratory access. [10-K 2026-03-13]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $8.0K | −$3.29M | −$2.90M | $0.00 | [10-Q 2026-08-07] |
| FY ended Dec 2025 | $14.8K | −$6.50M | −$5.73M | $0.00 | [10-K 2026-03-13] |
| FY ended Dec 2024 | $34.9K | −$8.38M | −$4.99M | $0.00 | [10-K 2026-03-13] |
- Quarterly cash burn
- −$1.45M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 40,439,810 | [10-Q 2024-11-13] |
| 2025-03-20 | 52,145,416 | [10-K 2025-03-20] |
| 2025-05-15 | 1,738,710 | [10-Q 2025-05-15] |
| 2025-08-14 | 1,763,129 | [10-Q 2025-08-14] |
| 2025-11-12 | 1,826,051 | [10-Q 2025-11-12] |
| 2026-03-13 | 2,959,469 | [10-K 2026-03-13] |
| 2026-05-15 | 2,959,469 | [10-Q 2026-05-15] |
| 2026-08-07 | 2,959,469 | [10-Q 2026-08-07] |
- Shelf registration
- S-3 filed 2025-02-07; declared effective 2025-02-14 [S-3 2025-02-07]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2024-12-04. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2024-12-04 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-12-04] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-18 | 8-K | Shareholder vote results |
| 2026-08-20 | 8-K | Regulation FD disclosure |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-08-05 | DEF 14A | Proxy statement |
| 2026-07-13 | PRE 14A | Proxy statement |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-03-13 | 10-K | Annual report |
| 2026-02-19 | 8-K | Regulation FD disclosure |
| 2025-11-12 | 10-Q | Quarterly report |
| 2025-10-15 | 8-K | Shareholder vote results |
Alerts for $CDIO
Email me when Cardio Diagnostics Holdings, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.